David N Krag
Overview
Explore the profile of David N Krag including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1961
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kopec J, Colangelo L, Land S, Julian T, Brown A, Anderson S, et al.
J Support Oncol
. 2012 Sep;
11(1):22-30.
PMID: 22951047
Background: The impact of arm morbidity following breast cancer surgery on patient-observed changes in daily functioning and health-related quality of life (HRQoL) has not been well-studied. Objective: To examine the...
22.
Gunzburg M, Ambaye N, Del Borgo M, Pero S, Krag D, Wilce M, et al.
J Mol Recognit
. 2012 Jan;
25(1):57-67.
PMID: 22213451
Src-homology (SH2) domains are an attractive target for the inhibition of specific signalling pathways but pose the challenge of developing a truly specific inhibitor. The G7-18NATE cyclic peptide is reported...
23.
Giricz O, Calvo V, Pero S, Krag D, Sparano J, Kenny P
Breast Cancer Res Treat
. 2011 Oct;
133(2):607-15.
PMID: 22005836
Triple-negative breast cancer (TNBC) is a heterogeneous disease that is usually associated with poor prognosis, and frequently associated with the basal-like breast cancer gene expression profile. There are no targeted...
24.
Sun Y, Shukla G, Kennedy G, Warshaw D, Weaver D, Pero S, et al.
J Biotech Res
. 2011 Aug;
1:55-63.
PMID: 21822461
Phage-display technology has been widely used for developing tumor-targeting agents. Laser capture microdissection (LCM) has proven to be an accurate method to select specific cells from histological sections. Our goal...
25.
Ambaye N, Pero S, Gunzburg M, Yap M, Clayton D, Del Borgo M, et al.
J Mol Biol
. 2011 Aug;
412(3):397-411.
PMID: 21802427
Growth-receptor-bound protein (Grb)7 is an adapter protein aberrantly overexpressed, along with the erbB-2 receptor in breast cancer and in other cancers. Normally recruited to focal adhesions with a role in...
26.
Weaver D, Ashikaga T, Krag D, Skelly J, Anderson S, Harlow S, et al.
N Engl J Med
. 2011 Jan;
364(5):412-21.
PMID: 21247310
Background: Retrospective and observational analyses suggest that occult lymph-node metastases are an important prognostic factor for disease recurrence or survival among patients with breast cancer. Prospective data on clinical outcomes...
27.
28.
Krag D, Anderson S, Julian T, Brown A, Harlow S, Costantino J, et al.
Lancet Oncol
. 2010 Sep;
11(10):927-33.
PMID: 20863759
Background: Sentinel-lymph-node (SLN) surgery was designed to minimise the side-effects of lymph-node surgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND). The aims of National Surgical Adjuvant Breast and...
29.
Land S, Kopec J, Julian T, Brown A, Anderson S, Krag D, et al.
J Clin Oncol
. 2010 Aug;
28(25):3929-36.
PMID: 20679600
Purpose: Sentinel lymph node resection (SNR) may reduce morbidity while providing the same clinical utility as conventional axillary dissection (AD). National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 is...
30.
Ashikaga T, Krag D, Land S, Julian T, Anderson S, Brown A, et al.
J Surg Oncol
. 2010 Jul;
102(2):111-8.
PMID: 20648579
Background And Objectives: Three year post-surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND) and those with negative sentinel node dissection and negative axillary...